Curis, Inc. (CRIS)

Curis, Inc.'s stock price has declined approximately 38.73% over the past six months. In May 2025, Curis reported Q1 earnings, with H.C. Wainwright initiating coverage with a "Buy" rating. In August 2025, Q2 financial results showed a reduced net loss and increased revenues, with plans to initiate a new clinical study. In November 2025, Curis provided a Q3 business update, reporting a reduced net loss and presentations at scientific meetings, but the stock price reached a 52-week low.

The demand for Curis, Inc.'s products and services is not subject to typical consumer-like seasonality. Demand for cancer treatments is driven by disease prevalence, diagnosis rates, and the efficacy and availability of approved therapies. Stock performance seasonality indicates that buying in August has the highest probability of a positive return, while February has the lowest.

Curis, Inc. is a biotechnology company focused on developing cancer therapeutics. Their pipeline includes Emavusertib (CA-4948), an IRAK4 kinase inhibitor in Phase 1/2 trials for AML, MDS, and PCNSL, which has received Orphan Drug Designation. Fimepinostat (CUDC-907) is a dual inhibitor of HDAC and PI3K enzymes for hematologic malignancies and solid tumors. CA-170 and CA-327 are oral antagonists targeting PD-L1 and VISTA immune checkpoints. Erivedge® (vismodegib) is an FDA-approved medicine for metastatic or locally advanced basal cell carcinoma, licensed to Genentech.

Curis, Inc. is headquartered in Lexington, Massachusetts, United States. The company focuses on the United States, specified countries in the European Union, and Japan through licensing agreements. Erivedge® is commercialized globally by Roche and Genentech. Curis also has a CRADA with the National Cancer Institute (NCI) for the joint development of CA-4948. Clinical studies for emavusertib are being conducted in countries like Spain, Germany, and Italy.

Specific information detailing Curis, Inc.'s brand reputation is not readily available. Its reputation is tied to the success and safety of its clinical pipeline and regulatory approvals. Positive clinical trial data and regulatory feedback contribute positively, while challenges in clinical development or financial performance could negatively impact its standing.

Curis, Inc.'s ownership is a mix of institutional, retail, and individual investors. Institutional investors hold approximately 24.54% to 29.97% of the stock. Insiders own about 5.45% to 9.19% of the stock, while public companies and retail investors hold a significant portion, ranging from 60.93% to 60.93%. Major institutional owners include Bleichroeder LP, Armistice Capital, LLC, and Vanguard Group Inc. Thomas Satterfield is a significant individual owner.